Legal Actions, Quarterly Dividends, Collaborations, and New Appointments - Research Report on Johnson & Johnson, Zoetis, Abbott, Teva Pharmaceuticals, and Baxter
NEW YORK, September 19, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Zoetis Inc. (NYSE: ZTS), Abbott Laboratories (NYSE: ABT), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), and Baxter International Inc. (NYSE: BAX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Johnson & Johnson Research Report
On September 12, 2013, Bloomberg reported that Johnson & Johnson (J&J) sued a unit of Boehringer Ingelheim Gmbh (Boehringer) over whether a dispute about an agreement to produce the cancer drug Doxil must be submitted to arbitration or not. The report stated that lawyers for New Brunswick, New Jersey-based J&J contend that executives of Boeringher's U.S. unit violated a 2009 agreement to produce Doxil and left J&J struggling to meet the demand. According to the release, J&J's Alza Corp. unit had hired Boehringer as its "sole-source manufacturer" of Doxil in 1995; however the production halted in 2011 when a Boehringer plant in Ohio was found to have quality issues by the U.S. FDA. As per the Bloomberg report, J&J officials are asking Delaware Chancery Judge Leo Strine to order Boehringer to honor its agreement to submit disputes over Doxil production to an arbitrator. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/07a8_JNJ]
--
Zoetis Inc. Research Report
On September 12, 2013, Zoetis Inc.' (Zoetis) Board of Directors declared its Q4 2013 dividend of c.$0.07 per share payable to holders of the Company's common stock. As per Zoetis, stockholders of record on November 1, 2013 will be paid the dividends on December 2, 2013. The Full Research Report on Zoetis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7e25_ZTS]
--
Abbott Laboratories Research Report
On September 12, 2013, Abbot Laboratories' (Abbott) Board of Directors declared a quarterly common dividend of $0.14 per share. As per Abott, the cash dividend will be payable on November 15, 2013 to shareholders of record at the close of business on October 15, 2013. Further, Abott stated this marks the 359th consecutive quarterly dividend to be paid by the Company since 1924. The Full Research Report on Abbott Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/05c1_ABT]
--
Teva Pharmaceutical Industries Ltd. Research Report
On September 16, 2013, Teva Pharmaceutical Industries Ltd (Teva Pharmaceuticals) announced a multi-project alliance agreement with Cancer Research Technology Ltd. (CRT) which is Cancer Research UK's technology development arm. According to the Company, the alliance has been formed to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells. Commenting on the partnership, Dr. Michael Hayden, President, Teva Global R&D and Chief Scientific Officer, stated, "For cancer patients, it is important that we maintain the momentum of progress that has been made in oncology in recent years. Cancer Research UK, CRT, and their outstanding academic partners, are a driving force in the improved understanding of cancer and its treatment. This research collaboration will build on our understanding of how cells repair DNA damage, help us identify possible points of therapeutic intervention, and lead us onto a pathway toward improve clinical outcomes for cancer patients." The Full Research Report on Teva Pharmaceutical Industries Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e3a3_TEVA]
--
Baxter International Inc. Research Report
On September 9, 2013, Baxter International Inc. (Baxter) announced the election of Todd S. Young by its Board of Directors as the Treasurer and Corporate Officer of the Company. Baxter informed that Young succeeds James K. Saccaro and will report to Baxter's CFO, Robert Hombach. According to the Company, Young joined Baxter in 2001 as corporate tax counsel, and over the years assumed positions of increasing responsibility, and prior to joining the new role, he served as Vice President, International Finance for the Company. The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/163d_BAX]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
Share this article